This market maker is now being implemented to increase liquidity of our stock, which has sometimes been low. We look very favorably on this support measure, which is primarily done to benefit our shareholders through reduced trading risks.
The acquisition of Rabeximod is the most important milestone since Cyxone was founded. I have been following Rabeximod's development in OxyPharma for a long time and believe that this investment is very beneficial for our shareholders. We have in a short time been able to build a world-class autoimmune product portfolio, which has permeated the discussions we have had with different stakeholders regarding the financing of Rabeximod's phase IIb study. This is why we are now taking the opportunity to complete the payment and hope to return soon to our shareholders with more positive news regarding Rabeximod.